Screener
Ionis Pharmaceuticals IONS Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $$47,704 | 28,082 |
| Accrued compensation | 50,293 | 116,236 |
| Accrued liabilities | 115,778 | 106,089 |
| Income taxes payable | 2,877 | 2,713 |
| 0 percent convertible senior notes due April 2026, net | - | 431,948 |
| Current portion of deferred contract revenue | 73,837 | 73,761 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's accrued manufacturing costs?
- Ionis Pharmaceuticals (IONS) reported accrued manufacturing costs of $50.29M in Q2 2026.
- How has Ionis Pharmaceuticals's accrued manufacturing costs changed year-over-year?
- Ionis Pharmaceuticals's accrued manufacturing costs increased by 8.0% year-over-year, from $46.56M to $50.29M.
- What is the long-term trend for Ionis Pharmaceuticals's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's accrued manufacturing costs has grown at a 12.1% compound annual growth rate (CAGR), from $65.73M to $116.24M.
Ask your AI about Ionis Pharmaceuticals's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude